In a recent announcement, Bandai Namco has revealed that the release of the Xbox One and PS4 ports of Shadow Warrior - the remake of 3D Realms' old shooter Shadow Warrior for the two new consoles - has been delayed until October.
The Xbox One and PS4 remake of the 1990s classic FPS was earlier scheduled to be launched in Europe on September 26, to be followed by the North America release of the game in the same month. However, the launch has now been postponed to October 24.
The PC version of the Shadow Warrior game was released last year. The release marked the next-generation version of Flying Wild Hog's reboot of the game.
With regard to the delay in the launch of the Xbox One and PS4 remake of Shadow Warrior, the Flying Wild Hog said that the reason prompting the push back of the game's launch to October is to add some more polish to the final product.
Flying Wild Hog said in a statement: "Bringing Shadow Warrior to PS4 and XB1 has proven to be a challenge for us as we want to make sure the player experience is perfect. In play testing we have been focusing in on the controller inputs and response."
There are a lot of things not going right at the IRS and mostly so when it comes to filing for Earned Income Tax Credits (EITC).
In December 2014, a report by Watchdog.org showed that that an audit by the IRS documented twenty four percent...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
In a blog post published on Wednesday, Twitter-owned...
A draft New York legislation proposes the use of a...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).